These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 27262335)

  • 21. Role of androgens in cardiovascular pathology.
    Chistiakov DA; Myasoedova VA; Melnichenko AA; Grechko AV; Orekhov AN
    Vasc Health Risk Manag; 2018; 14():283-290. PubMed ID: 30410343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploiting the Pleiotropic Antioxidant Effects of Established Drugs in Cardiovascular Disease.
    Steven S; Münzel T; Daiber A
    Int J Mol Sci; 2015 Aug; 16(8):18185-223. PubMed ID: 26251902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Longchain n-3 polyunsaturated fatty acids and blood vessel function.
    Abeywardena MY; Head RJ
    Cardiovasc Res; 2001 Dec; 52(3):361-71. PubMed ID: 11738053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Updates in antiplatelet agents used in cardiovascular diseases.
    Cheng JW
    J Cardiovasc Pharmacol Ther; 2013 Nov; 18(6):514-24. PubMed ID: 24213473
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Towards a comprehensive endothelial biomarkers profiling and endothelium-guided pharmacotherapy.
    Walczak M; Suraj J; Kus K; Kij A; Zakrzewska A; Chlopicki S
    Pharmacol Rep; 2015 Aug; 67(4):771-7. PubMed ID: 26321280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protease-activated receptors in cardiovascular health and diseases.
    Shah R
    Am Heart J; 2009 Feb; 157(2):253-62. PubMed ID: 19185631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monitoring oral antiplatelet therapy: is it justified?
    Ang L; Mahmud E
    Ther Adv Cardiovasc Dis; 2008 Dec; 2(6):485-96. PubMed ID: 19124443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An overview of commonly used antiplatelet agents.
    Bungard TJ
    Can J Cardiovasc Nurs; 1998; 9(3):38-46. PubMed ID: 10335141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cigarette Smoking and Atherosclerotic Cardiovascular Disease.
    Ishida M; Sakai C; Kobayashi Y; Ishida T
    J Atheroscler Thromb; 2024 Mar; 31(3):189-200. PubMed ID: 38220184
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of antiplatelet drugs in the prevention of cardiovascular events.
    Tendera M; Wojakowski W
    Thromb Res; 2003 Jun; 110(5-6):355-9. PubMed ID: 14592562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Thrombocyte inhibitors in cardiovascular therapy].
    Lüscher TF; Pfisterer M
    Schweiz Rundsch Med Prax; 1990 Sep; 79(39):1132-41. PubMed ID: 2218249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aspirin and P2Y12 Inhibitors in platelet-mediated activation of neutrophils and monocytes.
    Schrottmaier WC; Kral JB; Badrnya S; Assinger A
    Thromb Haemost; 2015 Aug; 114(3):478-89. PubMed ID: 25904241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease.
    Vorchheimer DA; Badimon JJ; Fuster V
    JAMA; 1999 Apr; 281(15):1407-14. PubMed ID: 10217057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiplatelet therapy with glycoprotein IIb/IIIa receptor inhibitors and other novel agents.
    Schafer AI
    Tex Heart Inst J; 1997; 24(2):90-6. PubMed ID: 9205981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The pleiotropic effects of antithrombotic drugs in the metabolic-cardiovascular-neurodegenerative disease continuum: impact beyond reduced clotting.
    Alaaeddine RA; AlZaim I; Hammoud SH; Arakji A; Eid AH; Abd-Elrahman KS; El-Yazbi AF
    Clin Sci (Lond); 2021 Apr; 135(8):1015-1051. PubMed ID: 33881143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endothelial Cells: From Dysfunction Mechanism to Pharmacological Effect in Cardiovascular Disease.
    Haybar H; Shahrabi S; Rezaeeyan H; Shirzad R; Saki N
    Cardiovasc Toxicol; 2019 Feb; 19(1):13-22. PubMed ID: 30506414
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis.
    Dzau VJ
    Hypertension; 2001 Apr; 37(4):1047-52. PubMed ID: 11304501
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resveratrol and endothelial function: A literature review.
    Parsamanesh N; Asghari A; Sardari S; Tasbandi A; Jamialahmadi T; Xu S; Sahebkar A
    Pharmacol Res; 2021 Aug; 170():105725. PubMed ID: 34119624
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abacavir induces platelet-endothelium interactions by interfering with purinergic signalling: A step from inflammation to thrombosis.
    Alvarez A; Rios-Navarro C; Blanch-Ruiz MA; Collado-Diaz V; Andujar I; Martinez-Cuesta MA; Orden S; Esplugues JV
    Antiviral Res; 2017 May; 141():179-185. PubMed ID: 28263802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.